Peptides built for rigorous research, sequence-verified, stability-tested, scale-flexible.

Yes. Custom sequence synthesis covers µg to kg scale, with non-standard modifications including PEG conjugation, fatty-acid lipidation, copper coordination, D-amino-acid incorporation, intramolecular disulfide bridging, and N/C-terminal modifications (acetyl, amide, biotin, etc.). The workflow runs: NDA + quote (1-3 days) → pilot synthesis at 100-500 mg gram-scale (4-6 weeks) → buyer validation → commercial-scale production (4-8 weeks). For sequences your lab has worked with previously, we can skip the pilot stage and run directly at commercial scale.

Standard release packet: batch-specific COA, HPLC chromatogram with peak integration showing ≥99.0% purity, ESI mass spec confirming molecular weight within 0.5 Da of theoretical, water content by Karl Fischer titration, counter-ion identification (acetate by default), and residual-solvent screening per pharmacopeia limits. For peptides above 15 residues, sequence verification by LC-MS/MS is included. Add-on tests on request: bacterial endotoxin (LAL per USP <85>) for in vivo workflows, microbial limits (USP <61>/<62>), stability data (accelerated and/or real-time), and bioactivity confirmation (where appropriate to the molecule).

For catalog research peptides at standard fill sizes (2-15 mg lyophilized vials), inventory-held SKUs ship in 5-10 business days from confirmed PO. Made-to-order catalog SKUs run 14-21 days. Custom-synthesized sequences run 4-8 weeks for first-time orders and 10-14 days for repeat orders against an established synthesis route. Expedited lead time is available at a 30-50% premium when production needs to be sequenced into existing schedule. For procurement workflows planning multiple experiments, ordering against forecast against an established route is the most lead-time-efficient pattern.

Yes. Academic, government-laboratory, and non-profit research pricing is reviewed case-by-case at quote stage. The pricing model typically reflects the buyer's order frequency and total annual volume rather than a uniform discount; small but recurring orders may price better than large one-off purchases because the procurement-economics advantage of recurring scheduling outweighs the per-batch volume premium. Discuss your lab's procurement profile at quote stage so we can match the pricing approach to your purchase cadence.

Yes. Acetate is the default counter-ion across the catalog because it's the pharmaceutically and analytically preferred form for most downstream research and clinical workflows. TFA-salt material is available on explicit request for the narrow research workflows that need it (some structural-biology purification workflows, specific receptor-pharmacology studies where TFA is a known variable). Other counter-ions (mesylate, hydrochloride, citrate, sulfate) are available through the OEM service for buyers with specific formulation requirements. Specify the counter-ion at quote stage; the released-batch COA always reports the explicit counter-ion identification.